{
    "organizations": [],
    "uuid": "13a95ed1882d2854d5e88d6b356b1cc71afcc30a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-soligenix-driving-towards-key-infl/brief-soligenix-driving-towards-key-inflection-points-with-two-pivotal-phase-3-clinical-trials-idUSASB0C2BQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Soligenix - Driving Towards Key Inflection Points With Two Pivotal Phase 3 Clinical Trials",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 40 PM / Updated 22 minutes ago BRIEF-Soligenix - Driving Towards Key Inflection Points With Two Pivotal Phase 3 Clinical Trials Reuters Staff 1 Min Read \nJan 25 (Reuters) - Soligenix Inc: \n* SOLIGENIX - DRIVING TOWARDS KEY INFLECTION POINTS WITH TWO PIVOTAL PHASE 3 CLINICAL TRIALS Source text for Eikon: Further company coverage:",
    "published": "2018-01-25T14:38:00.000+02:00",
    "crawled": "2018-01-25T15:06:34.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "driving",
        "towards",
        "key",
        "inflection",
        "point",
        "two",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "soligenix",
        "inc",
        "soligenix",
        "driving",
        "towards",
        "key",
        "inflection",
        "point",
        "two",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}